期刊文献+

膀胱移行细胞癌组织中PSCA和Oct-4表达及其意义 被引量:3

Expressions of prostate stem cell antigen and Oct-4 and their clinicopatholgical significances in transitional cell cancer of bladder
下载PDF
导出
摘要 目的研究膀胱移行细胞癌和癌旁正常移行上皮组织中前列腺干细胞抗原(PSCA)和Oct-4表达水平及其临床病理意义。方法收集45例膀胱移行细胞癌和10例癌旁正常膀胱移行上皮组织标本常规制作石蜡切片,以PSCA和Oct-4标志物进行EnV ision免疫组织化学法染色。结果膀胱移行细胞癌PSCA和Oct-4表达阳性率(55.6%;53.3%)明显高于癌旁正常膀胱移行上皮组织(PSCA:10.0%,2χ=6.81,P=0.009;Oct-4:10.0%,2χ=6.20,P=0.013)。病理分级0~Ⅰ级、临床分期Tris-T1、初发病例及单发病例PSCA和Oct-4表达阳性率明显低于病理分级Ⅱ~Ⅲ级、临床分期Ⅱ~Ⅳ、复发病例及多发病例(P〈0.05或P〈0.01)。膀胱移行细胞癌中PSCA和Oct-4表达呈高度一致性(2χ=7.88,P=0.005)。结论 PSCA和Oct-4可能是反映膀胱移行细胞癌发生、进展、侵袭潜能及预后的重要生物学标志物。 Objective To study the expression levels of PSCA and Oct-4 and detect their clinicopathological significances in the peritumoral normal transitional epitheli and transitional cell cancer of bladder.Methods EnVisiom immunohistochemical method was used to assay the expression levels of PSCA and Oct-4 in the routinely paraffin-embedded sections from the resected specimens of transitional cell cancer(n=45),peritumoral normal transitional epitheli(n=10).Results The positive rates of PSCA and Oct-4 were higher in transitional cell cancer than those in pericancerous normal transitional epitheli(PSCA:55.6% vs 10.0%,χ2=6.81,P=0.009;Oct-4:53.3%,χ2=6.20,P=0.013).The positive rates of PSCA and Oct-4 were significantly lower in pathological grade 0~Ⅰ,clinical stage Tris-T1,primary cases and singlet mass than those in the pathological grade Ⅱ~Ⅲ,clinical stage T2-T4,recurrent cases and multiple mass(P0.05 or P0.01).The high consistence was found among the expressions of PSCA ans Oct-4 in transitional cell cancer(χ2=7.88,P=0.005).Conclusion PSCA and Oct-4 might be important biological markers for reflecting the carcinogenesis,progression,invasive potential and prognosis of transitional cell cancer of bladder.
出处 《实用肿瘤杂志》 CAS 北大核心 2010年第5期531-534,共4页 Journal of Practical Oncology
关键词 膀胱肿瘤 前列腺干细胞抗原 OCT-4 预后 免疫组织化学 bladder neoplasms prostate stem cell antigen Oct-4 immunohistochemsitry prognosis
  • 相关文献

参考文献14

  • 1Zhiyang Z, Wenlu S. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer [ J]. Prostate,2007,67(6) :653 - 660.
  • 2杨轶凡,孔祥波,谷欣权,王春喜.前列腺干细胞抗原在人前列腺癌组织中的表达及意义[J].中国老年学杂志,2006,26(7):886-888. 被引量:11
  • 3Trosko JE. From adult stem cells to cancer stem cells: Oct4 gene,cell-cell communication, and hormones during tumor promotion[ J ]. Ann N Acad Sci, 2006,1089 ( 1 ) : 36 -58.
  • 4Grubbs EG, Abdel-wahab Z, Tyler DS, et al. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer [ J]. Ann Surg Oncol,2006,13 ( 12): 1645 - 1654.
  • 5Elsamman EM, Fukumori T, Tanimoto S, et al. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma, a quantiative reverse transcriptase-poly, merase chain reaction analysis [ J ]. BJU Int,2006,98 ( 3 ) : 668 - 673.
  • 6Elsamman EM,Fukumori T, Dasai T, et al. Prostate stem cell antigen predicts tumor recurrence in superfical transitional cell carcinoma of the urinary bladder [ J ]. BJU Int, 2006,97 ( 6 ) : 1202 - 1207.
  • 7Attasi Y,Mowla SJ,Ziaee SA,et al. Oct-4, an embryonic stem cell marker, is highly expressed in bladder cancer [J]. Int J Cancer,2007,120(7) :1598 - 1602.
  • 8Roman G. The role of adult stem cells in carcinogenesis [J]. Drug News Perspect, 2005,18(9) :555 -559.
  • 9Kruse C, Kajahn J,Petschnik AE,et al. Adult pancreatic stem/progenitor cells spontaneously differentiated in vitro into multiple cell lineages and form teratoina-like structures [ J ]. Ann Anat,2006,188 ( 6 ) : 503 - 517.
  • 10Li Q, Yang Z . Expression of phosphor-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations [ J ]. J Exp Clin Cancer Res ,2009,28 ( 1 ) :65 -72.

二级参考文献9

  • 1Lalani el-N,Laniado ME,Abel PD.Molecular and cellular biology of prostate cancer[J].Cancer Metastasis Rev,1997;16(1-2):29-66.
  • 2Reiter RE,Gu Z,Watabe T,Thomas G,et al.Prostate stem cell antigen:a cell surface marker overexpressed in prostate cancer[J].Proc Natl Acad Sci USA,1998;95(4):1735-40.
  • 3Dannull J,Diener PA,Prikler L,et al.Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer[J].Cancer Res,2000;60(19):5522-8.
  • 4Ross S,Spencer SD,Lasky LA,et al.Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis[J].Am J Pathol,2001;158(3):809-16.
  • 5Ross S,Spencer SD,Holcomb I,et al.Prostate stem cell antigen as therapy target:tissue expression and in vivo efficacy of an immunoconjugate[J].Cancer Res,2002;62(9):2546-53.
  • 6Saffran DC,Raitano AB,Hubert RS,et al.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts[J].Proc Natl Acad Sci USA,2001;98(5):2658-63.
  • 7Thomas G,Yamashiro J,Shintaku IP,et al.Prostate stem cell antigen (PSCA) expression increases with high gleason score,advanced stage and bone metastasis in prostate cancer[J].Oncogene,2000;19(10):1288-96.
  • 8Han KR,Seligson DB,Liu X,et al.Prostate stem cell antigen expression is associated with gleason score,seminal vesicle invasion and capsular invasion in prostate cancer[J].J Urol,2004;171(3):1117-21.
  • 9Lam JS,Yamashiro J,Shintaku IP,et al.Prostate stem cell antigen is overexpressed in prostate cancer metastases[J].Clin Cancer Res,2005;11(7):2591-6.

共引文献10

同被引文献45

  • 1Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Mu- rakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113:631-642.
  • 2Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res 2004; 105:442-447.
  • 3Gure AO, Stockert E, Scanlan MJ, Keresztes RS, Jager D, Altorki NK, Old LJ, Chen YT. Serological identification of embryonic neural proteins as high- ly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 2000; 97:4198-4203.
  • 4Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E. Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 2005; 102:9601-9606.
  • 5Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immu- nohistochemical analysis of gastric epithelial tran- scription factor SOX2: comparison of expression patterns between invasive components and cancer- ous or nonneoplastic intraductal components. Pan- creas 2006; 32:164-170.
  • 6Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lan- cet Oncol 2002; 3:508-513.
  • 7Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogram- ming of human somatic cells to pluripotency with defined factors. Nature 2008; 451:141-146.
  • 8Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith A. Formation of pluripotent stem cells in the mam- malian embryo depends on the POU transcription factor Oct4. Cell 1998; 95:379-391.
  • 9Zhang J, Wang X, Chen B, Suo G, Zhao Y, Duan Z, Dai J. Expression of Nanog gene promotes NIH3T3 cell proliferation. Biochem Biophys Res Commun 2005, 338:1098-1102.
  • 10Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 2000; 16:182-187.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部